pathology-ai
(2)
Harrison.ai
Harrison.ai is a Sydney-based clinical AI company founded in 2018 by brothers Dr Aengus Tran and Dimitry Tran. It builds artificial-intelligence software that helps clinicians read medical images faster and more accurately - flagging urgent findings on chest X-rays and brain and chest CT scans, and streamlining pathology review. Its diagnostic products, radiology brand annalise.ai and pathology joint venture franklin.ai, are used at more than 1,000 healthcare sites across four continents, with regulatory clearance in 40-plus countries. The company positions itself as a builder of foundation models for medicine, releasing harrison.rad.1, a radiology-specific multimodal large language model. Harrison.ai raised a US$112 million Series C in February 2025 to fund a US expansion, taking total capital raised past US$240 million.
Valar Labs
Valar Labs is a Palo Alto precision-oncology company building AI tests that read the pathology slides already made during routine cancer care. Its Vesta platform applies proprietary foundation models to standard H&E-stained tissue images to predict how individual patients will respond to therapy - starting with bladder cancer, where it forecasts whether a patient is likely to benefit from BCG treatment and stratifies the risk of recurrence and progression. Founded in 2021 by Stanford AI researchers, the company has raised $26M total and earned the FDA's first Breakthrough Device Designation for an AI digital-pathology prognostic test in bladder cancer.